Skip to main content

Table 1 Characteristics of selected trials

From: The influence of gender on the effects of aspirin in preventing myocardial infarction

Author (year) Trial name Participants Sample size Mean age at baseline (year) Current smoker (%) Male (%) Follow-up (year) Aspirin dose (mg/day)
Ridker et al [26] (2005) Women's Health Study (WHS) Healthy women ≥ 45 years in USA 39 876 55 13 0 10.0 100†
de Gaetano [19] (2001) Primary Prevention Project (PPP) Patients with at least one of the major recognized cardiovascular risk factors in Italy 4 495 64 15 42 3.6 100
Cote et al [18] (1995) Asymptomatic Cervical Bruit Study (ACBS) Patients with asymptomatic carotid stenosis in Canada 372 67 37 45 2.3 325
ETDRS Study Group [13] (1992) Early Treatment Diabetic Retinopathy Study report (ETDRS) Patients with a clinical diagnosis of diabetes mellitus 3 711 18–70 44# 52 5.0 650
Juul-Moller et al [24] (1992) Swedish Angina Pectoris Aspirin Trial (SAPAT) Patients with chronic stable angina 2 035 67 16 52 4.2 75
Hansson et al [23] (1998) Hypertension Optimal Treatment Study (HOT) Patients with hypertension and diastolic blood pressure between 100 mmHg and 115 mmHg from countries in Europe, America, and Asia 18 790 62 16 53 3.8 75
Swedish cooperative [8] (1987) Swedish Cooperative Study (Swedish Coop) Patients with cerebral infarction, minor or major stroke 505 68 52 62 2.0 1 500
EAFT Study Group [14] (1993) European Atrial Fibrillation Trial (EAFT) Patients with non-rheumatic atrial fibrillation 782* 73 19 63 2.3 300
SALT Collaborative Group [11] (1991) Swedish Aspirin Low-Dose Trial (SALT) Patients after transient ischaemic attack (TIA) or minor stroke 1 360 67 25 66 2.7 75
Cairns et al [17] (1985) Canadian multicenter trial (Canadian) Patients with unstable angina who were hospitalized in coronary care units in Canada 278* 57 35 70 1.5 1 300
Stroke Prevention in Atrial Fibrillation Study group [12] (1991) Stroke Prevention in Atrial Fibrillation Study (SPAF) Patients with constant or intermittent atrial fibrillation 1 120* 67 16 71 1.3 325
Sorensen et al [27] (1983) A Danish cooperative study (Danish Coop) Patients experienced at least one reversible cerebral ischemic attack 203 59 24¶ 73 2.0 1 000
Farrell et al [22] (1991) United Kingdom transient ischaemic attack aspirin trial (UK-TIA) Patients with a transient ischaemic attack or minor ischaemic stroke 2 435 60 53 73 4.0 300/1 200
Persantine-Aspirin Reinfarction Study Research Group [5] (1980) Persantine-aspirin Reinfarction Study (PARIS) Patients recovered from myocardial infarction 1 216* 56 27 77 3.4 972
Breddin et al [16] (1980) German-Austrian aspirin trial (GAAT) Patients who had survived a myocardial infarction for 30–42 days 626 45–70 58 78 2.0 1 500
Elwood and Sweetnam [21] (1979) Aspirin and secondary mortality after myocardial infarction (Cardiff-II) Patients with confirmed myocardial infarction 1 725‡ 56 60 85 1.0 900
AMIS Study Group [6] (1980) Aspirin myocardial infarction study (AMIS) Patients experienced at least one myocardial infarction in USA 4 524 55 27 89 3.0 1 000
Elwood et al [20] (1974) Secondary prevention of mortality from myocardial infarction (Cardiff-I) Patients with recent myocardial infarction 1 239‡ 55 NA 100 1.1 300
Coronary Drug Project Research Group [7] (1980) Coronary Drug Project Aspirin Study (CDPA) Patients with a history of myocardial infarction 1 529‡ NA NA 100 1.8 324
Lewis et al [25] (1983) Veterans Administration Cooperative Study (VACS) Patients with unstable angina in USA 1 266 56 50 100 1.0 324
Steering Committee of the Physicians' Health Study Research Group [9] (1989) Physicians' Health Study (PHS) Healthy male physicians in USA 22 071 52 11 100 5.0 325†
The RISC Group [10] (1990) Research Group on Instability in Coronary Artery Disease (RISC) Men with unstable coronary artery disease in Southeast Sweden 796* 58 38 100 1.0 75
Medical Research Council's General Practice Research Framework Group [15] (1998) Thrombosis prevention Trial (TPT) Patients at high risk of cardiovascular disease in UK 2 540 58 41 100 4.0 75
  1. NA: not available.
  2. *Only the participants in placebo group and aspirin group were included.
  3. † Every other day.
  4. ‡ Data are from [4].
  5. ¶ > 15 cigarettes/day.
  6. # ≥ 6 cigarettes/day.
\